Chronic myeloid leukaemia Initial PBS authority application Imatinib mesylate, accelerated or blast phase application Supporting information form (PB082)

You must lodge this form for a patient starting initial PBS subsidised treatment with imatinib mesylate for either accelerated or blast phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript BCR-ABL tyrosine kinase.

Page last updated: 15 June 2016

This information was printed Tuesday 27 September 2016 from humanservices.gov.au/health-professionals/forms/pb082 It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.